8-K: Ligand Pharmaceuticals Completes Acquisition of XOMA Royalty

Ligand Pharmaceuticals Incorporated has finalized its acquisition of XOMA Royalty Corporation, with XOMA Royalty stockholders receiving $39.00 per share in cash and a Contingent Value Right.

Summary

• Ligand Pharmaceuticals Incorporated has completed its acquisition of XOMA Royalty Corporation.
• The transaction, announced on April 27, 2026, involved Ligand acquiring all outstanding shares of XOMA Royalty common stock.
• XOMA Royalty stockholders received $39.00 in cash per share.
• Additionally, stockholders and equity award holders received a non-transferable Contingent Value Right (CVR) per share.
• The CVR entitles holders to a portion of 75% of net proceeds from certain pending litigation at XOMA Royalty.
• As a result of the acquisition, XOMA Royalty's common stock has ceased trading on the Nasdaq stock exchange.
• The company also announced the termination of its Loan Agreement with XRL 1 LLC as borrower, with all outstanding obligations fully discharged.
• The acquisition involved a Holding Company Reorganization and a Merger, with HoldCo surviving as a wholly owned subsidiary of Ligand.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for XOMA Royalty shareholders due to the cash payout and the inclusion of a CVR, indicating a successful exit, though the delisting and contingent nature of the CVR introduce some caution.

Positives

• XOMA Royalty stockholders received a cash payment of $39.00 per share.
• Stockholders and equity award holders will receive a Contingent Value Right (CVR) providing potential future proceeds from litigation.
• The acquisition by Ligand Pharmaceuticals provides a clear exit for XOMA Royalty shareholders.
• The Loan Agreement with XRL 1 LLC has been fully terminated and discharged, removing outstanding obligations.

Negatives

• XOMA Royalty's common stock has been delisted from the Nasdaq stock exchange, ending its public trading.
• The value of the CVR is contingent on the outcome of pending litigation, introducing uncertainty.
• The acquisition means XOMA Royalty will no longer operate as an independent entity.

Risks

• Risks related to the ability to realize the anticipated benefits of the acquisition.
• Potential for the businesses not to be integrated successfully.
• Disruption from the transaction may make it more difficult to maintain business and operational relationships.
• Significant transaction costs and unknown liabilities.
• Risk of litigation and/or regulatory actions related to the acquisition or XOMA Royalty's business.
• Uncertainties regarding the commercial success of XOMA Royalty's and Ligand's pipeline products.
• Risks associated with drug development and reliance on collaborative partners for milestone payments and royalties.
• Potential for unfavorable new clinical data or differing interpretations of clinical trial data by regulatory authorities.

Future Outlook

The filing contains forward-looking statements regarding Ligand's acquisition of XOMA Royalty and their respective product pipelines, acknowledging substantial risks and uncertainties that could cause actual results to differ materially. These include risks related to integration, realization of benefits, litigation, regulatory actions, and the commercial success of pipeline products.

Management Comments

• Ligand Pharmaceuticals Incorporated has completed its previously announced acquisition of XOMA Royalty.
• XOMA Royalty stockholders received $39.00 in cash per share of XOMA Royalty common stock owned.
• XOMA Royalty stockholders and equity award holders also received one non-transferable Contingent Value Right (CVR) per share.
• As a result of the transaction completion, XOMA Royalty's common stock no longer trades on the Nasdaq stock exchange.

Industry Context

StockSavvy.ai notes that this acquisition represents a significant consolidation within the biotechnology royalty aggregation sector, a space focused on providing non-dilutive funding to biotech companies by acquiring future economics of therapeutic candidates. Ligand's move to acquire XOMA Royalty suggests a strategy to expand its portfolio and potentially leverage synergies in managing and monetizing these royalty assets.

Management Changes

Legal Proceedings

• Certain pending litigation at XOMA Royalty, from which CVR holders may receive proceeds.

Stakeholder Impact

• Shareholders: Received $39.00 cash per share and a CVR, but their shares are no longer publicly traded.
• Equity Award Holders: Received CVRs and had awards converted to corresponding awards with respect to HoldCo common stock.
• Creditors: Loan Agreement obligations were fully discharged.
• Employees: Potential integration impacts and changes in management structure.

Next Steps

• Ligand Pharmaceuticals will integrate XOMA Royalty's assets and operations.
• XOMA Royalty's common stock will remain delisted from Nasdaq.
• Holders of CVRs will await potential future proceeds from pending litigation.
• Ligand will continue to manage and develop its combined product pipeline.

Key Dates

Recommendation

The acquisition by Ligand Pharmaceuticals provides a definitive cash exit for XOMA Royalty shareholders at a premium ($39.00 per share), which is a positive outcome. However, the inclusion of a Contingent Value Right (CVR) tied to litigation introduces an element of uncertainty regarding future returns. The delisting of XOMA Royalty's stock means it will no longer be directly tradable. For existing XOMA Royalty shareholders, holding the CVR and observing the outcome of the litigation is the primary path forward. For potential investors in Ligand, this acquisition is a strategic move that needs to be evaluated within Ligand's broader portfolio and integration plans.

Keywords

XOMA Royalty, Ligand Pharmaceuticals, Merger, Acquisition, CVR, Preferred Stock, Nasdaq, Form 8-K